Madgdalena Abakanowicz: The godmother of installation art – Christie’s

Magdalena Abakanowicz (1930-2017) was born into a landed family of rich, Polish gentry. The familys fortunes were transformed by the Second World War, with the Abakanowiczes forced to flee their country estate once Communist rule was imposed on Poland by the Soviet Union. They took with them only the coins they could sew into their clothing.

The family settled in a tiny apartment in Warsaw, the city where Magdalena would enrol in the Academy of Fine Arts aged 20. Discouraged by her professors from pursuing painting, she turned to weaving instead then deemed a more appropriate practice for women.

In later life, Abakanowicz reflected that this had actually been a positive thing. The state-approved painting style, Socialist Realism, would have been limiting for her artistically, demanding as it did scenes glorifying Communist life. Works in fabric, by contrast, came under little scrutiny, meaning she had considerable creative freedom.

In the 1960s, the artist found success with a radical set of tapestries that were unlike anything previously seen. Known as Abakans, these tapestries were not flat, genteel offerings intended to tell a story or decorate a wall, but roughly-woven, abstract tangles of sisal fibre, imposingly hung from the ceiling. They won her the Grand Prize at 1965s So Paulo Biennial.

Abakanowiczs fame soon spread far beyond Poland, and she began to move away from weaving her own structures, using burlap instead, which she gnarled and stretched. From the mid-1970s, her work also became characterised by groups of intriguing, frequently unsettling, humanoid figures known as Alterations. The series culminated in the landmark sequence Embryology, shown in the Polish Pavilion at the 1980 Venice Biennale.

When examining man, I am in fact examining myself, she said. My forms are the skins I strip off myself one by one, marking the milestones along my road.

Over time, her figures would proliferate in bronze, stone, wood and clay, while invitations came to exhibit in museums and public spaces worldwide, including Edinburgh Cathedral; the roof garden of the Metropolitan Museum; and Grant Park in Chicago (where her piece, Agora, is permanently installed).

This summer, a major Abakanowicz retrospective opens at Londons Tate Modern. Its curator, Ann Coxon, agreed to give us a sneak preview.

Why is Magdalena Abakanowicz such an important artist?

Ann Coxon: She was a pioneer of what we now call installation art. There wasnt a name for it back in Abakanowiczs heyday, for the simple reason that it was something very new at the time.

You can call her works tapestries, but what she was creating, above all, were experiential environments. Weve become used to installation today [through works by everyone from Yayoi Kusama to Olafur Eliasson], but it once was an extraordinary development. And Abakanowicz was a godmother of that. Her pieces create a reaction not just because of what they are, but because of where they are.

So you prefer not to focus on the part she played in the so-called Fibre art movement of the 1960s and 1970s?

AC: Thats certainly the way that many, over the years, have seen her [alongside Sheila Hicks and Claire Zeisler] as one of a group of female artists who created textile works in connection to gender politics. Abakanowicz wasnt a feminist, though, or she wouldnt have identified as one. She didnt want her art to be defined solely in terms of female practice. Her concerns were richer and broader than that.

Given her privileged background, did she have many run-ins with the Soviet Bloc authorities?

AC: She actually seems to have been well-supported by the state. They granted her a decent-sized studio in Warsaw, for example, as well as a visa to travel, neither of which were easily come by. I think it helped that she played down her well-to-do background. At art school, she chose to assume the fake identity of a clerks daughter.

What can visitors expect from the Tate exhibition?

AC: Our show-stoppers will be the Abakans. Well have somewhere between 15 and 20 displayed together in one gallery, which should be quite something, given that just 30 exist.

Politics are bound up in her work, but Abakanowicz was never overtly political, either as a person or an artist curator Ann Coxon

Its often said that the Abakans are named as such because thats a contracted version of Abakanowicz. But the point is that there really were no words around at the time to describe these stunning, hanging structures [which the artist hand-wove and hand-dyed, and are an average of 15 feet tall and five feet wide]. Abakans seemed as good a name as any. Theyre big, spectacle-hungry things that usually were exhibited in sets [rather than individually, so as to create a sense of both monumentality and penetrability, as visitors walk under and around them].

After the Abakans, Abakanowicz moved onto series in which she surveyed the human body: such as Heads (1973-75), Seated Figures (1976) and Backs (1976-82), which consisted of a group of anonymous figures, arranged in geometric order and depending on the series distinguished by being headless, limbless, sexless or expressionless. Might we interpret these figures politically as victims of totalitarian oppression and the death of individuality under Communism?

AC: I think politics are certainly bound up in her work, but Abakanowicz was never overtly political, either as a person or an artist. She couldnt afford to be initially; but even after the fall of Communism in the early 1990s she refused to attach explicit, political meaning to her art. Just as she refused to attach explicit, autobiographical meaning either.

By autobiographical, are you referring to incidents like that during the Second World War when a drunk German soldier burst into the family home and shot Magdalenas mothers arm off?

AC: Yes, or the fact that she never had children, which some critics have used as the prism through which to view her Embryology series. The installations in Embryology feature multiple, rounded forms of different sizes: forms that, to those critics eyes, look like cocoons or embryos or kinds of new-born creatures. Even though, to other eyes, they look more like potatoes!

Sign up today

Christies Online Magazine delivers our best features, videos, and auction news to your inbox every week

Subscribe

Magdalenas works are ambiguous and highly evocative and all the more powerful for not being literal depictions of actual people or things. They evoke humankind in general, humankind in its entirety.

Magdalena Abakanowicz at Tate Modern, London, runs from 17 June to 13 September

Original post:
Madgdalena Abakanowicz: The godmother of installation art - Christie's

PharmaForce International: New Product Launches and Additional Indication Approvals Lead to an Increase in Immunology Personnel – BioSpace

READING, Pa., Jan. 23, 2020 /PRNewswire/ -- PharmaForce International (PFI) recently completed a study that benchmarks the leading Immunology sales and marketing organizations in the United States. The report focuses on key companies with products competing across the Dermatology, Rheumatology, and Gastroenterology markets throughout 2019. Since the previous Immunology report published by PFI in 2018, the profiled companies have experienced a 25 percent increase in the total number of commercial operations personnel that are dedicated to Immunology. This includes various roles such as sales, marketing, field medical, market access, field reimbursement, and upper-level management.

Additional profiled company trends since the 2018 report include:

Joyce Wedemeyer, Director of Marketing and Sales at PharmaForce International, says that this increase in personnel is due to new product launches and additional indication approvals for existing products.

"The majority of these profiled companies have expanded their dedicated Immunology personnel in the anticipation of launching new products into the market or having additional indications approved. These expansions are strategic approaches to ensure better positioning versus the competitive products," says Wedemeyer.

PFI plans to further the focus on Immunology benchmarking in 2020. The United States Immunology report will be updated again, as well as a report on the five major EU countries. Both studies are expected to be completed and available to clients by December.

For more information on the reports mentioned above, please contact Joyce Wedemeyer at Joyce.Wedemeyer@strategicreports.comor by phone at 610-370-2906.

PharmaForce International (PFI) is a competitive intelligence firm with over two decades of experience in the pharmaceutical and biotech industries. PFI has become the market leader in commercial operations benchmarking and competitive intelligence.

View original content to download multimedia:http://www.prnewswire.com/news-releases/pharmaforce-international-new-product-launches-and-additional-indication-approvals-lead-to-an-increase-in-immunology-personnel-300992342.html

SOURCE PharmaForce International

See the rest here:
PharmaForce International: New Product Launches and Additional Indication Approvals Lead to an Increase in Immunology Personnel - BioSpace

Key trends that will shaped the immunology market in the last decade, according to GlobalData – PharmiWeb.com

From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry.

Patrick Aiyes, Senior Immunology Analyst at leading data and analytics company GlobalData, observes the key trends that has shaped the immunology market in the last decade:

Key immunology drugs

The immunology market has seen a continuous increase in the sales of interleukin inhibitors and a decrease in the sales of TNF inhibitors - primarily because of the entry of biosimilars into the market and the increased safety profile associated with interleukin inhibitors. Abbvies Humira will end the decade as the highest grossing drug of 2019, generating sales of approximately $19bn globally, while Janssens Stelara will be the highest-grossing interleukin inhibitor in the market.

JAK inhibitors have also been a very popular drug in the immunology space. After the approval of Pfizers Xeljanz in RA in 2012, Eli Lillys Olumiant and Abbvies Rinvoq have followed suit. Although this class of drugs boasts a great efficacy profile and a fast onset of action, there has been controversy surrounding its safety and this has been a key topic in the latter years of the decade. Long-term studies are needed to see if this class of drugs will be useful in the next ten years.

Improvement in research

In the last decade, there has been a breakthrough in research surrounding diseases that have not had therapies approved. For example, in atopic dermatitis (AD) Sanofis Dupixient was approved in 2017, while Benlysta was approved for systemic lupus erythematosus (SLE) in 2011.

There have been many breakthrough and fast-track designations assigned by the US Food and Drug Administration (FDA) to promising drugs in diseases where there is a lack of safe and efficacious agents. Over the last ten years, graft versus host disease (GvHD) saw as many as nine drugs assigned breakthrough or fast-track designations, while AD saw six drugs, and SLE saw five. This is primarily because therapies with specific targets are now being introduced to help patients treatments.

Biosimilar disruption

The increasing prevalence of biosimilars has noticeably had a negative impact on mainstay biologics, including Janssens Remicade and Abbvies cash cow, Humira, which faced the introduction of biosimilars in Europe in 2018. In 2019, biosimilars will generate sales of over $3.4bn, with Pfizers Inflectra generating a whopping $671m.

On the disruption caused by biosimilars, big pharma is most at-risk from the arrival of biosimilar competition. However, many have invested in their own biosimilar pipelines to offset risk, typically through partnerships. Biosimilars were mainly brought in to help reduce the cost of very expensive drugs, while this strategy is working in Europe, there is still more to be done in order to keep healthcare costs low in the US.

About GlobalData

4,000 of the worlds largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalDatas unique data, expert analysis and innovative solutions, all in one platform. GlobalDatas mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.

The rest is here:
Key trends that will shaped the immunology market in the last decade, according to GlobalData - PharmiWeb.com

L2P Research (Former AJES Life Sciences, LLC) and Transcell Oncologics, LLC Announce Partnership to Provide High Quality Hu-CB-CD34 and Hu-PBMC to…

ANNVILLE, Pa.--(BUSINESS WIRE)--L2P Research, LLC and Transcell Oncologics, LLC have entered into a partnership with the purpose of marketing and the distribution of Transcell Oncologics, LLC Trans HSC (CD34+), Trans-HSC (PBMC) product line and L2P Researchs humanized mouse models.

L2P Research, LLC is a Pennsylvania based Research organization founded with a vision to provide integrated R&D support in all the key areas of Pharmaceutical development. L2P provides a complete array of research services as required for Investigational New Drug Applications (IND). Transcell Oncologicss Transtoxbio portfolio (www.transtoxbio.com) is all about human sourced primary progenitor cell based predictive platforms that work for exploratory drug and cosmetics research meant for clinics.

The agreed terms of this partnership highlight the product line dealing with CD34+ cells and Humanized mouse models, the scope of joint business development utilizes both companys capabilities jointly to address demand, quality, fit with preclinical research grade stem cells ( For Academia, Pharma, Contract Research Organizations) in the USA.

CAT# TRANS-HSC-CBM; CAT#TRANS-HSC-CBCD34; CAT#TRANS-HSC-PBCD34Represent the CD34+ cells available lots.

CAT#TRANS-HSC-HMRepresent the humanized mouse models available to the user.

CD34+ cells and the cell based humanized animal models market is projected to reach $ 200 M by 2022 with their applications shown in Oncology, Immunology, Infectious Diseases, Neuroscience, Toxicology, and Hematopoiesis by the user.

This specific partnership between Transcell Oncologics and L2P Research is confident to address the existing gap seen between the demand and the quality of supply owing to respective groups advantageous positions and credibility dealing with right kind of cells and the animal models.

Read the original post:
L2P Research (Former AJES Life Sciences, LLC) and Transcell Oncologics, LLC Announce Partnership to Provide High Quality Hu-CB-CD34 and Hu-PBMC to...

Oxford Immunotec Announces Donation in Support of Coronavirus Testing Efforts to Help Differentiate Tuberculosis from the New China Virus – BioSpace

OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the Company), a global, high-growth diagnostics company, today announced they are planning a new initiative to commemorate the coming World Tuberculosis Day, bring the benefits of the T-SPOT.TB test to mainland China and assist with differentiating tuberculosis (TB) from other respiratory infections. Oxford Immunotec will donate tests approximately valued at CNY 3,000,000 to Chinese hospitals through a non-profit organization, Bethune Charitable Foundation, in support of their efforts to combat the outbreak of the coronavirus.

Because some pathogens present with similar symptoms as TB, ruling out TB quickly in infected suspects is critical to fighting the spread of the infection. Since its approval in the Peoples Republic of China in 2010, T-SPOT.TB has been recognized for its high level of sensitivity and specificity across patient populations and has become a critical aid in the diagnosis of TB infection.

The donation plan is supported by leading hospitals and KOLs in China. Prof. Mou Xiangdong, Director of Respiratory and Critical Care Department, Beijing Tsinghua Chang Gung Hospital says, We would like to thank Oxford Immunotec for their commitment to the Chinese people. As symptoms of some infections may be similar to TB, this test will help us differentiate these illnesses with greater accuracy during epidemic seasons.

About T-SPOT.TB

The T-SPOT.TB test is available in over 60 countries and recognized by the World Health Organization (WHO) as one the 100 essential diagnostic tests that should be available in every country. In China, the T-SPOT.TB test has been on the market since 2010 and has been rapidly adopted by the leading hospitals and physicians as a critical tool for diagnosing TB infection. Today more than 250 of Chinas top hospitals rely on the T-SPOT.TB test to determine treatment for hard to diagnose patients. There is no comparable technology with similar sensitivity and specificity on the market in China. The T-SPOT.TB test is relied on as an essential tool in the fight against TB.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Companys T-SPOT.TB test has been approved for sale in over 60 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at http://www.oxfordimmunotec.com.

CONTACTS:

For Media and Investor Inquiries: Matt McLaughlinChief Financial OfficerOxford ImmunotecTel: +1 (508) 573-9953mtmclaughlin@oxfordimmunotec.com

Continued here:
Oxford Immunotec Announces Donation in Support of Coronavirus Testing Efforts to Help Differentiate Tuberculosis from the New China Virus - BioSpace

New Investments Expected To Boost The Z-drugs Market Between ‘ 2019’ And ‘2027’ Dagoretti News – Dagoretti News

Global Z-drugs Market Introduction

Nonbenzodiazepines, commonly referred as Z-drugs, are a widely prescribed class of psychoactive drugs for the treatment of different types of sleep disorders, particularly insomnia, which affects millions of people across the world. These drugs have similar effects as benzodiazepines by potentiating GABA (gamma-aminobutyric acid) activity in the body.

Global Z-drugs Market Competitive Landscape

Teva Pharmaceutical Industries Ltd., Sanofi, and Pfizer, Inc. are the major players operating in the global Z-drugs market. New product development and focus on emerging markets where the prevalence of insomnia is high are the strategies adopted by these players to increase market share.

Report Overview @https://www.transparencymarketresearch.com/z-drugs-market.html

Teva Pharmaceutical Industries, Ltd.

Teva Pharmaceutical Industries Ltd. is a key manufacturer of generic medicines and a recognized leader in innovative and specialty pharmaceuticals across the globe. The company delivers high quality and patient-centric health care solutions. It has a broad generics portfolio, with more than 1,000 molecules in nearly every therapeutic area. It continues to evaluate opportunities for joint ventures, collaborations, and other activities that support growth. Teva Pharmaceutical Industries focuses on establishing leadership position in its core therapeutic areas of respiratory (including asthma & COPD) and CNS through business development initiatives such as acquisition of Labrys Biologics in 2014 and Auspex Pharmaceuticals, Inc. in 2015.

Pfizer, Inc.

Pfizer, Inc. operates through two business segments: Pfizer Innovative Health and Pfizer Essential Health. The company has been issued 129 patents in the U.S. and 1,807 in the rest of the world for its products. It offers products in multiple therapeutic areas such as endocrinology, neurology, immunology, oncology, HIV, rare diseases, and hematology in more than 125 countries. Pfizer, Inc. has developed a strong supply chain network, which is directly responsible for addressing the patients needs. With technological advancements, the company tracks movement of products throughout the entire supply chain.

Sanofi

Sanofi is a global provider of health care solutions. The company has broad product portfolio that caters to areas such as rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes, cardiovascular diseases, vaccines, and consumer health care. Sanofi focuses on acquisitions, in-licensing, and collaborations with key players in the market to reinforce its product pipeline. The company emphasizes on strategic reshaping of the product portfolio in order to strengthen its position in developed and emerging markets.

Global Z-drugs Market Dynamics

Large Patient Pool of Sleep Disorder Drives Demand for Z-drugs

Sleep disorder is a health concern for a larger percentage of the general population of the world. According to the Journal of Family Medicine and Primary Care, prevalence of sleep disorder is 10% to 30% of the global population, and insomnia in particular is on the rise. It is common in older adults, women, and people with medical and mental ill health. Such large population base of sleep disorder, especially insomnia, drives demand for Z-drugs.

Major Side Effects of Z-drugs to Hamper Market

Users of nonbenzodiazepines have reportedly experienced side effects such as short-term memory loss, sleepwalking, sleep driving, dizziness, headache, back pain, and rashes. This induces them to stop taking the drugs for long-term treatment, which in turn hampers sales of the drugs.

North America Dominated Global Z-drugs Market in 2018

According to the National Sleep Foundation, insomnia is the most common sleep disorder in the U.S. Moreover, around 40 million people in North America are affected by insomnia each year. The foundation also stated that prevalence of insomnia has increased among women and older adults in the region. Availability of drugs, high awareness about the effects of sleep disorder, and high prevalence of sleep disorders drive demand for Z-drugs in North America.

For More Details, Request A PDF Brochure Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=71355

Global Z-drugs Market Segmentation

In terms of, the global Z-drugs market can be classified into:

Based on application, the global Z-drugs market can be categorized into:

In terms of distribution channel, the global Z-drugs market can be divided into:

See more here:
New Investments Expected To Boost The Z-drugs Market Between ' 2019' And '2027' Dagoretti News - Dagoretti News

The Best Wool Socks According to Experts – GearJunkie

On a mission to track down the best pairs of wool socks, we sought help from the pros.

Wool has long been touted as the best material for overall warmth and odor resistance during outdoor pursuits. These pros love their choice wool socks for breathability, comfort, and long lifespans.

From ice climbing and ski mountaineering in the Rockies to polar adventures at the worlds farthest ice caps and running the hardest ultramarathons on the planet, here are the top five best wool socks according to the experts.

Polar adventurer and expedition guide Eric Larsen is the first person in history to complete expeditions to the South Pole, the North Pole, and the Mount Everest summit in a continuous 365-day period. He also accomplished the first-ever summer expedition to the North Pole.

Keeping all 20 digits healthy is pretty important on those self-supported missions in the coldest environments on the planet. The best sock, in Larsens experience, is the Wigwam Ice Sock.

I got my first pair in 2008. Ive had a few pairs since then, but, usually, I get about 2-3 years use out of one pair, he said. That means Larsen wears a single pair on a polar expedition for nearly 2 months straight.

So, in a single year, hell use that pair for 3-5 months of polar travel and training. He prefers the Wigwam for polar expeditions to the North and South poles, teaching his polar training course, crossing the Greenland ice cap you know, common everyday athletic pursuits as well as ice fishing and dog sledding.

They are a simple wool knit that breathes incredibly, he noted. They are a heavier, thick sock, so they provide more insulation than any other sock Ive ever used and are super durable. I dont use them in lightweight hiking boots, but in pack boots and my polar boots they are amazing.

Shop Now

Got cold feet? Use these ten tips from Polar Explorer Eric Larsen to keep your feet warm in the winter and cold weather. Read more

Chantelle Robitaille, an endurance coach at Carmichael Training Systems, recently earned her master of science degree in High Altitude Exercise Physiology. She has also worked as an exercise physiologist and researcher at Colorados Western Colorado University, near where she lives. When shes not doing science, she races 100-mile ultramarathons across the world.

Im a big fan of the Point6 Colorado Mini Crew, said Robitaille, who got the pair as a Valentines Day gift about 4 years ago. The socks are ideal for running, biking, and hiking. She loves them so much that shes since bought a variety of other Point6 socks, including ski and compression.

This is the only brand of wool socks Ive owned that dont get a hole in the big toe within a few wears.They are never too hot or too cold and never get stinky.I even wore a pair of Point6 socks while pacing at Badwater 135 this summer. If a pair of socks can withstand one of the worlds toughest footraces, we approve.

Shop Now

Professional skimo racer and trail runner Cam Smith is based in Crested Butte, Colorado. Hes a member of the U.S. Ski Mountaineering team and a two-time winner of the Grand Traverse Triple Crown.

I havea few pairs of Darn Tough socks that are my absolute go-to all winter long, said Smith. His favorite? Smith uses the Darn Tough Mountain Top Over-The-Calf Cushionfor all types of skiing from alpine to backcountry to nordic.

Theyre warm enough for sitting on chairlifts but light and breathable enough for skinning hard up a mountain. Hell even wear them in the summer on cold mornings while camping or for predawn runs.

The little bit of extra cushion adds comfort, which is nice when youre in ski boots all day. I find theyre great in any cold-weather activity, he said.

Theyre 2 years old and show only a few signs of wear despite being shoved into my ski boots for hours and hours all winter. Darn Tough also has an awesome lifetime warranty, and if I ever needed to I could exchange them at a local shop.

Shop Now

Master bootfitter Sam Tischendorf helps skiers from all over the world hone their ski boot fit at Bootdoctors Telluride and as a national Masterful University Instructor. Shes the only female master bootfitter in the entire United States.

For ski boots, thin, even knitting and consistent thickness around the foot is the most ideal type of sock, she explained. I wear wool socks for everything skiing, snowboarding, running, biking, and kicking around town. My most memorable is a pair of FITS Micro Light. They can get wet but dont irritate my feet or cause friction in my shoes.

Tischendorf got the socks about four summers ago, and they were a staple for her mountain endeavors. They just sprung a hole this summer, so theyre relegated to being worn with boots and jeans, she said.

Shop Now

Dawn Glanc is an AMGA-certified rock and alpine guide. Specializing in mixed and ice terrain, veteran Glanc has been a professional climber for more than 20 years. A resident of Ouray, Colorado, shes among the earliest wave of female ice climbers to push the sport, including first ascents in the Westfjord of Iceland and becoming the first woman in the Americas to climb M11.

A pair of tall socks from Darn Tough are my favorite wool socks, said Glanc of the now 10-year-old Vertex Over-the-Calf Ultra-Light. She wears these socks year-round in the summer as hiking socks and in winter for skiing as well as ice and mixed climbing.

For length, she prefers tall for the functionality and extreme fashion.The socks will not wear out! They have outlasted every other pair of socks I have had, she said.

Shop Now

From hiking boots to snow boots, these are the best men's winter boots of 2020; Including top picks from Sorel, KEEN, Kamik, and more. Read more

We tested and reviewed the best women's winter boots of 2020. Check out winter hiking boots and snow boots from Kamik, Bogs, and more. Read more

Excerpt from:
The Best Wool Socks According to Experts - GearJunkie

In the wake of the Fukushima nuclear disaster, some animals are thriving – The Hill

It has been nearly nine years since the Fukushima Daiichi nuclear power plant nuclear disaster, and while people still remain evacuated from the areas most contaminated by radioactivity, many wonder: What happened to the wildlife left behind?

A newly released study by a team of scientists from the University of Georgia and Fukushima University found that years after the disaster at Fukushima, populations of mid-to-large-sized mammals and birds are thriving in the absence of human pressure.

The March 11, 2011, nuclear disaster in Japans Fukushima Prefecture caused by the tsunami that resulted from a massive magnitude-9 earthquake was one of the worst nuclear plant disasters in human history, second only to the 1986 Chernobyl incident in Ukraine.

A wild boar. Courtesy of the University of Georgia.

Through remotely operated, motion-activated cameras placed at 106 sites, researchers saw that some species like raccoons and wild boar were more abundant in the humans excluded zone the most contaminated area people are not allowed to live in when compared to the humans restricted zone where people have returned and the humans inhabited zone that was never evacuated.

The fact that animals seem to be doing well at a population level is counterintuitive. I mean, these are very contaminated landscapes, says James Beasley, the wildlife ecology professor at the University of Georgia who led this project. He says the popular movie or video game perception of abandoned nuclear wastelands is not exactly real life at Fukushima or Chernobyl.

Beasley and the team went to the Fukushima exclusion zone in 2016 to begin this camera study. They set up the cameras across the landscape, including the zone in which people can no longer live because the radiation dose rates are still above the recommended safety threshold.

Even in the most contaminated zones of the field site, Beasley says, it is still safe to set up the cameras if one doesnt linger too long. They wear heavy rubber boots and an alarm that sounds if a certain radiation dose rate is exceeded.

It's okay to put a camera up for a few minutes and then move on. But, you know, that's not the sort of place you want to stop and have your lunch, for example, he adds.

Macaque monkeys. Courtesy of the University of Georgia

Caught on Camera

The observation period lasted for 120 days from 2016 to 2017, and in that time, more than 267,000 photos were captured on the motion-activated cameras. In total, 20 species of mammal and birds were spotted roaming across the three zones surveyed.

Out of all the animals spotted on the cameras, wild boar showed up in the human-excluded zone the most in more than 26,000 of the images to be precise. This is not exactly surprising, Beasley says, because wild boar are opportunistic and reproduce at a high rate. In comparison, wild boar were caught on camera more than 7,200 times in the human-inhabited region during the observation period.

Red foxes, masked palm civets, green pheasant, Japanese macaques, Japanese hares and raccoon dogs were all captured on the cameras. The one lucky camera snap of a baby macaque riding on its mothers back is not just adorable, it is evidence reproduction is happening in this area despite the contamination.

A Japanese serow. Courtesy of the University of Georgia

Timothy Mousseau, a biology professor at the University of South Carolina, was not involved in this study, but also does similar research in Fukushima and Chernobyl. He says the findings in this study reflect what he has seen in his own work in Fukushima: that population-wise, human presence can impact animal abundance more than the radiation effects.

He says the massive clean-up effort of the area was likely a large disturbance for animals in the region. All of this noise and dust and human activity seems to be a much bigger factor shaping the abundance and distribution of the mammals than the radiation effects, says Mousseau.

A hare. Courtesy of the University of Georgia

This study examines the population-level impacts of the disaster and not the molecular-level impacts of radiation. Beasley says while there may not be enough of an impact on physiology or reproduction from the radiation to suppress the population, they will conduct more research on animal health at Fukushima in the future to learn more.

Mousseau did a study on barn swallows in Fukushima shortly after the disaster in 2011 and found they did have genetic damage, but it was minimal. Another study on genetic damage in earthworms and wild boars shows there are molecular impacts of radiation exposure, but these studies need to be continued over time to see if this DNA damage manifests at the population level.

In this case at Fukushima, the inverse correlation of human presence and animal abundance indicates people leaving the area has a positive impact on the rewilding of the landscape, which is similar to findings from longterm wildlife abundance studies in Chernobyl.

Many of the organisms like the birds and insects were pretty dramatically impacted in the first year or two after the accident, Mousseau says. But now, the main message can be optimism.

It's clear that many of these organisms have come back...these areas can self-remediate just by being left alone for a little while.

A badger. Courtesy of the University of Georgia

Read more:
In the wake of the Fukushima nuclear disaster, some animals are thriving - The Hill

Reelin reverts main pathological processes related to Alzheimer’s and other tauopathy – Mirage News

Image of a primary neuronal cell culture with detection of MAP2 dendritic marker (red) and Neurofilament axon marker (green).

Promoting the signalling pathway of reelin an essential extracellular protein for the neuronal migration and synaptic plasticity- could be an effective therapeutical strategy to counterbalance the main cognitive, biochemical and behavioural alterations seen in Alzheimers and other pathologies associated with Tau protein, as shown in a new study with animal models published in the journal Progress in Neurobiology.

The study proves the determining role of reelin in the modulation of pathological processes associated with Alzheimers and other tauopathies (accumulation of amyloid plaques, aberrant distribution of Tau phosphorylated, synaptic dysfunction and memory loss), and opens a new perspective to design future therapeutical targets and drugs to fight these disorders.

The first author of this study is the researcher Daniela Rossi, and it is led by Eduardo Soriano and Llus Pujadas, members of the Faculty of Biology and the Institute of Neurosciences (UBNeuro) of the University of Barcelona, the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) and the Vall dHebron Research Institute (VHIR).

Other participants are the experts Agns Gruart, Jos M Delgado and Gerardo Contreras-Murillos (University Pablo de Olavide), Jess vila (Center for Molecular Biology Severo Ochoa, CBM), and Ashraf Muhaisen (UB-UBNeuro-CIBERNED-VHIR). This new study on neurosciences counts on the support of the Research Challenges program (Biomedicine) from the Spanish Ministry of Economy and Competitiveness (MINECO) and La Marat de TV3.

Reelin, an essential protein for brain plasticity

Alzheimers disease is a neurodegenerative disease known for the loss of connection between neurons and neuronal death. It is largely linked to the creation of senile plaques (formed by the amyloid-beta peptide, or A), and the presence of neurofibrillary balls (insoluble deposit of Tau).

In the adult brain, the loss of reelin has been related to an increase in the phosphorylation of Tau protein a factor which is related to the microtubules mainly expressed in neurons- which ends up in neurofibrillary ball form typical from Alzheimers.

Therefore, the different states of phosphorylation and dephosphorylation of Tau represent a determining factor in the stability of the cell cytoskeleton and, as a result, of the synaptic and dendritic stability. Hyperphosphorilation and accumulation of Tau causes neuronal death.

In this context, the function of the reelin protein to promote synaptic plasticity and reduce Tau phosphorylation was considered a potential mechanism to reduce the consequences of the neurodegenerative process and protect the brain from neuronal damage.

New beneficial effects of reelin in animal models with tauopahy

In previous studies, experts had affirmed the alteration of reelin in Alzheimers disease and its role in intracellular signalling pathways related to neuronal survival and the physiology of the adult brain. Researchers had described the active role of reelin in the recovery of cognitive functions and the reduction of fibers of the A peptide in vitro and amyloid deposit in the brain in animal models with Alzheimers (Pujadas et al. Nature Communications, 2014).

The published study in Progress in Neurobiology describes new molecular data on the signalling pathway of reelin and reveals how this protein can reverse the main pathological affectations of Alzheimers at different levels in animal models affected by tauopathies. In particular, the results reveal that overexpression of reelin is able to modulate levels of phosphorylation of the Tau protein in in vivo models.

Moreover, the in vitro studies confirm the ability of reelin to modulate the anomalous distribution of neurofilaments and Tau protein in dendrites, which is shown in the first phases of these neuropathologies. Last, regarding the cognitive and physiological fields, overexpression of reelin revealed an improvement of deficits that affected a new animal model of tauopathy.

Article reference:

Rossi, D.; Gruart, A.; Contreras-Murillo, G; Muhaisen, A.; vila, J.; Delgado-Garca, J.; Pujadas, L.; Soriano, E. Reelin reverts biochemical, physiological and cognitive alterations in mouse models of Tauopathy. Progress in Neurobiology, December, 2019. Doi: https://doi.org/10.1016/j.pneurobio.2019.101743

See the original post here:
Reelin reverts main pathological processes related to Alzheimer's and other tauopathy - Mirage News

Mota Ventures Forms Research and Development Partnership with Leading Colombian University & Research Hospital – GuruFocus.com

VANCOUVER, BC / ACCESSWIRE / January 23, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the "Company") is pleased to announce that its wholly owned subsidiary Ihuana S.A.S ("Ihuana") has entered into a research cooperation agreement (the "Agreement") with La Fundacion Universitaria de Ciencias de la Salud (The University Foundation of Health Sciences) (the "University") located in Bogota, Colombia. Pursuant to the Agreement, the parties intend to engage in research and formulation of medicinal products made with non-psychoactive cannabis and cannabis byproducts.

The University is a not-for-profit private educational and health care university founded in 1976. Between their two locations, including a Children's Hospital in San Jose, the University has the necessary technology for highly specialized medical and surgical treatments including an automated clinical laboratory, diagnostic imaging, neurological sciences, internal medicine and outpatient care. Additionally, the foundation offers laboratories in biology, biochemistry, anatomy, physiology, genetics, immunology, histology, microbiology and clinical stimulation.

Ihuana and the University will cooperate in the development of scientific investigations related to the medical use of products made with cannabis. The research teams from both groups will work closely to design and execute studies, with the University providing the infrastructure and connections to different researchers and Ihuana supplying various resources, including testing materials. Cost of the research will be negotiated between the two parties for each individual research product and intellectual property from the study will be divided based on capital input from each side.

The University agrees to enable access and interaction with partner hospitals and research centers that will take part in clinical studies and trials and will allow access to institutional resources to finance research through existing relationships.

"This partnership gives us an immediate foothold in the medicinal market in Colombia. We are very fortunate to partner with one of the leading universities in South America. This will allow for rapid development of new products for the domestic and international markets," stated Joel Shacker, CEO of the Company.

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota Ventures a seeking to become a vertically integrated, revenue-producing CBD company with operations in both Europe and North America. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota Ventures.

About the University Foundation of Health Sciences

The University Foundation of Health Sciences is a modernized private educational and health care university founded in 1976. Between two locations, including a Children's Hospital in San Jose, the University has the necessary technology for highly specialized medical and surgical treatments including an automated clinical laboratory, diagnostic imaging, neurological sciences, internal medicine and outpatient care. Additionally, the foundation offers laboratories in biology, biochemistry, anatomy, physiology, genetics, immunology, histology, microbiology and clinical stimulation.

ON BEHALF OF THE BOARD OF DIRECTORSMOTA VENTURES CORP.

Joel ShackerChief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [emailprotected] or http://www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including with respect to research and development projects with the University, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally and its plans to acquire revenue-producing CBD brands and operations in Europe and North America. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company's public filings under the Company's SEDAR profile at http://www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

SOURCE: Mota Ventures Corp.

View source version on accesswire.com: https://www.accesswire.com/573898/Mota-Ventures-Forms-Research-and-Development-Partnership-with-Leading-Colombian-University-Research-Hospital

Go here to see the original:
Mota Ventures Forms Research and Development Partnership with Leading Colombian University & Research Hospital - GuruFocus.com